--- schema_version: "secwatch.filing_event.v1" accession: "0001193125-26-257501" form_type: "8-K" ticker: "SRPT" cik: "0000873303" company_name: "Sarepta Therapeutics, Inc." filed_at: "2026-06-04T20:29:44+00:00" generated_at: "2026-06-04T20:59:49.985353+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.5 calibrated_materiality_score: 0.5 confidence: "high" source: SEC EDGAR --- # Sarepta shareholders approve 2026 equity plans; elect directors at annual meeting ## Summary - 2026 Equity Incentive Plan approved: 63.2M for, 4.4M against; 6,286,841 shares reserved. - 2026 Employee Stock Purchase Plan approved: 67.1M for, 0.5M against; 1.5M shares reserved. - Five Class I directors elected: Ingram, Wigzell, Boor, Chambers, Connelly. Connelly had 14.2M against. - Advisory vote on named executive officer compensation passed: 45.2M for, 22.4M against. - Ratification of KPMG as independent auditor approved: 79.9M for, 2.1M against. ## SEC filing metadata - accession: 0001193125-26-257501 - form_type: 8-K - ticker: SRPT - cik: 0000873303 - company_name: Sarepta Therapeutics, Inc. - filed_at: 2026-06-04T20:29:44+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.5 - calibrated_materiality_score: 0.5 - confidence: high - sec_items: 5.02, 5.07, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/873303/000119312526257501/0001193125-26-257501-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/873303/000119312526257501/d88936d8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001193125-26-257501 - JSON: https://secwatch.observer/filing/0001193125-26-257501.json - Plain text: https://secwatch.observer/filing/0001193125-26-257501.txt ## Key facts - Shareholder Votes Sarepta Therapeutics, Inc. shareholders approved Election of Directors at the 2026-06-04 meeting. - Proposal: director election - Outcome: passed - Meeting: 2026-06-04 source text: Proposal 1: Election of Directors The director nominees listed below were elected to serve on the Company’s board of directors as members of Class I for a term of two years. The results of the vote were as follows: Name of Nominee For Against Abstain Broker Non-Votes Douglas S. Ingram 66,812,593 827,973 52,441 14,616,281 Hans Wigzell, M.D., Ph.D. 56,984,756 10,663,180 45,071 14,616,281 Kathryn J. Boor, Ph.D. 63,915,239 3,722,626 55,142 14,616,281 Michael Chambers 65,892,431 1,752,077 48,499 14,616,281 Deirdre Connelly 53,419,881 14,213,242 59,884 14,616,281 evidence_url: https://www.sec.gov/Archives/edgar/data/873303/000119312526257501/0001193125-26-257501-index.htm - Shareholder Votes Sarepta Therapeutics, Inc. shareholders approved Approval of the Company's 2026 Equity Incentive Plan at the 2026-06-04 meeting. - Proposal: equity plan - Outcome: passed - Meeting: 2026-06-04 source text: Proposal 3: Approval of the Company ’s 2026 Equity Incentive Plan The stockholders approved the 2026 Plan. The results of the vote were as follows: For Against Abstain Broker Non-Votes 63,233,193 4,395,283 64,531 14,616,281 evidence_url: https://www.sec.gov/Archives/edgar/data/873303/000119312526257501/0001193125-26-257501-index.htm - Shareholder Votes Sarepta Therapeutics, Inc. shareholders approved Ratification of KPMG as the Company's Independent Registered Public Accounting Firm at the 2026-06-04 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2026-06-04 source text: Proposal 5: Ratification of KPMG as the Company ’s Independent Registered Public Accounting Firm The stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the current year ending December 31, 2026. The results of the vote were as follows: For Against Abstain 79,907,368 2,110,136 291,784 evidence_url: https://www.sec.gov/Archives/edgar/data/873303/000119312526257501/0001193125-26-257501-index.htm - Shareholder Votes Sarepta Therapeutics, Inc. shareholders approved Advisory Vote to Approve Named Executive Officer Compensation at the 2026-06-04 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2026-06-04 source text: Proposal 2: Advisory Vote to Approve Named Executive Officer Compensation The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers for 2025. The results of the advisory vote were as follows: For Against Abstain Broker Non-Votes 45,185,398 22,373,065 134,544 14,616,281 evidence_url: https://www.sec.gov/Archives/edgar/data/873303/000119312526257501/0001193125-26-257501-index.htm - Shareholder Votes Sarepta Therapeutics, Inc. shareholders approved Approval of the Company's 2026 Employee Stock Purchase Plan at the 2026-06-04 meeting. - Proposal: equity plan - Outcome: passed - Meeting: 2026-06-04 source text: Proposal 4: Approval of the Company ’s 2026 Employee Stock Purchase Plan The stockholders approved the 2026 ESPP. The results of the vote were as follows: For Against Abstain Broker Non-Votes 67,098,699 532,525 61,783 14,616,281 evidence_url: https://www.sec.gov/Archives/edgar/data/873303/000119312526257501/0001193125-26-257501-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.